| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 18 | 2019 | 899 | 2.210 |
Why?
|
| Diabetic Retinopathy | 11 | 2017 | 64 | 2.100 |
Why?
|
| Cardiovascular Diseases | 27 | 2019 | 1007 | 1.830 |
Why?
|
| Mobility Limitation | 11 | 2019 | 187 | 1.760 |
Why?
|
| Blood Pressure | 15 | 2019 | 803 | 1.610 |
Why?
|
| Antihypertensive Agents | 11 | 2019 | 338 | 1.590 |
Why?
|
| Weight Loss | 11 | 2018 | 413 | 1.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 17 | 2018 | 1374 | 1.350 |
Why?
|
| Obesity | 14 | 2018 | 1062 | 1.270 |
Why?
|
| Hypoglycemic Agents | 9 | 2017 | 175 | 1.180 |
Why?
|
| Exercise | 13 | 2018 | 587 | 1.140 |
Why?
|
| Aged | 62 | 2019 | 9462 | 1.130 |
Why?
|
| Losartan | 3 | 2019 | 68 | 0.930 |
Why?
|
| Interleukin-6 | 6 | 2019 | 224 | 0.910 |
Why?
|
| Humans | 89 | 2019 | 29013 | 0.910 |
Why?
|
| Male | 70 | 2019 | 17768 | 0.900 |
Why?
|
| Female | 68 | 2019 | 18114 | 0.870 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 52 | 0.860 |
Why?
|
| Life Style | 10 | 2017 | 363 | 0.860 |
Why?
|
| Renal Insufficiency, Chronic | 8 | 2019 | 266 | 0.850 |
Why?
|
| Sample Size | 4 | 2012 | 37 | 0.840 |
Why?
|
| Middle Aged | 47 | 2019 | 10805 | 0.800 |
Why?
|
| Thiazolidinediones | 4 | 2017 | 47 | 0.760 |
Why?
|
| Exercise Therapy | 8 | 2017 | 229 | 0.710 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 68 | 0.700 |
Why?
|
| Self Efficacy | 4 | 2017 | 70 | 0.690 |
Why?
|
| Macular Edema | 4 | 2017 | 14 | 0.680 |
Why?
|
| Visual Acuity | 4 | 2017 | 66 | 0.650 |
Why?
|
| Research Design | 6 | 2019 | 285 | 0.650 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 103 | 0.640 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2019 | 134 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 373 | 0.640 |
Why?
|
| Walking | 8 | 2017 | 177 | 0.580 |
Why?
|
| Inflammation | 7 | 2019 | 503 | 0.560 |
Why?
|
| Patient Selection | 3 | 2019 | 257 | 0.550 |
Why?
|
| Aged, 80 and over | 19 | 2019 | 3712 | 0.530 |
Why?
|
| Risk Factors | 22 | 2019 | 3509 | 0.530 |
Why?
|
| Kidney Tubules | 3 | 2019 | 25 | 0.520 |
Why?
|
| Motor Activity | 5 | 2015 | 310 | 0.510 |
Why?
|
| Body Mass Index | 7 | 2015 | 862 | 0.490 |
Why?
|
| Patient Care Planning | 1 | 2014 | 53 | 0.470 |
Why?
|
| Informed Consent | 1 | 2013 | 51 | 0.460 |
Why?
|
| Genetic Testing | 1 | 2013 | 89 | 0.460 |
Why?
|
| Body Image | 1 | 2012 | 13 | 0.450 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 25 | 0.440 |
Why?
|
| Self Concept | 1 | 2012 | 41 | 0.440 |
Why?
|
| Uncertainty | 1 | 2012 | 12 | 0.430 |
Why?
|
| Quality of Life | 5 | 2017 | 815 | 0.430 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 88 | 0.400 |
Why?
|
| Ethnic Groups | 1 | 2013 | 440 | 0.400 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 298 | 0.400 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 358 | 0.390 |
Why?
|
| Risk Reduction Behavior | 3 | 2017 | 115 | 0.380 |
Why?
|
| Blood Glucose | 5 | 2018 | 465 | 0.380 |
Why?
|
| Longitudinal Studies | 6 | 2018 | 708 | 0.350 |
Why?
|
| Aging | 5 | 2017 | 880 | 0.340 |
Why?
|
| Diet, Reducing | 5 | 2013 | 90 | 0.340 |
Why?
|
| Double-Blind Method | 5 | 2019 | 501 | 0.330 |
Why?
|
| Treatment Outcome | 12 | 2018 | 3099 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 462 | 0.310 |
Why?
|
| Psychotherapy, Group | 2 | 2004 | 15 | 0.310 |
Why?
|
| Overweight | 3 | 2013 | 256 | 0.310 |
Why?
|
| Counseling | 2 | 2004 | 85 | 0.300 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 2106 | 0.300 |
Why?
|
| Body Composition | 5 | 2017 | 365 | 0.300 |
Why?
|
| Sacroiliac Joint | 1 | 2007 | 13 | 0.300 |
Why?
|
| Glomerular Filtration Rate | 5 | 2019 | 286 | 0.290 |
Why?
|
| Low Back Pain | 1 | 2007 | 36 | 0.290 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2018 | 104 | 0.290 |
Why?
|
| Calcium Channel Blockers | 2 | 2018 | 49 | 0.280 |
Why?
|
| Pilot Projects | 4 | 2019 | 469 | 0.280 |
Why?
|
| Pain Measurement | 2 | 2007 | 360 | 0.280 |
Why?
|
| Blood Pressure Determination | 4 | 2019 | 94 | 0.270 |
Why?
|
| Cognition | 3 | 2017 | 524 | 0.270 |
Why?
|
| Bone and Bones | 2 | 2018 | 87 | 0.270 |
Why?
|
| Age Factors | 6 | 2018 | 1105 | 0.260 |
Why?
|
| Epilepsy | 2 | 2003 | 59 | 0.260 |
Why?
|
| Sex Factors | 6 | 2018 | 626 | 0.260 |
Why?
|
| Sodium | 3 | 2019 | 37 | 0.250 |
Why?
|
| Incidence | 7 | 2018 | 1105 | 0.250 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 863 | 0.250 |
Why?
|
| Diabetic Angiopathies | 3 | 2014 | 137 | 0.250 |
Why?
|
| Gene Frequency | 1 | 2004 | 225 | 0.240 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 706 | 0.240 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 355 | 0.230 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2003 | 5 | 0.230 |
Why?
|
| Muscle Spasticity | 1 | 2003 | 24 | 0.220 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2003 | 27 | 0.220 |
Why?
|
| Biometry | 1 | 2002 | 12 | 0.220 |
Why?
|
| Botulinum Toxins | 1 | 2003 | 37 | 0.220 |
Why?
|
| Education, Medical, Continuing | 1 | 2002 | 45 | 0.220 |
Why?
|
| Time Factors | 7 | 2018 | 1997 | 0.220 |
Why?
|
| Stroke | 2 | 2017 | 522 | 0.210 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 40 | 0.210 |
Why?
|
| Fractures, Bone | 2 | 2015 | 149 | 0.210 |
Why?
|
| Adult | 17 | 2017 | 8391 | 0.210 |
Why?
|
| Catheterization, Central Venous | 1 | 2002 | 60 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2014 | 59 | 0.200 |
Why?
|
| Cross-Sectional Studies | 6 | 2019 | 1353 | 0.200 |
Why?
|
| Single-Blind Method | 6 | 2018 | 165 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 836 | 0.200 |
Why?
|
| Disability Evaluation | 3 | 2018 | 210 | 0.190 |
Why?
|
| Physicians | 1 | 2002 | 134 | 0.190 |
Why?
|
| Bayes Theorem | 3 | 2017 | 66 | 0.190 |
Why?
|
| Simvastatin | 2 | 2018 | 25 | 0.190 |
Why?
|
| Software | 2 | 2015 | 109 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2002 | 259 | 0.180 |
Why?
|
| Resistance Training | 2 | 2017 | 70 | 0.180 |
Why?
|
| Disease Management | 2 | 2018 | 114 | 0.180 |
Why?
|
| European Continental Ancestry Group | 3 | 2013 | 1131 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 28 | 0.170 |
Why?
|
| Health Education | 3 | 2016 | 121 | 0.170 |
Why?
|
| United States | 7 | 2019 | 3604 | 0.170 |
Why?
|
| Parathyroid Hormone | 1 | 2018 | 38 | 0.170 |
Why?
|
| Hyperglycemia | 3 | 2014 | 82 | 0.170 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 34 | 0.170 |
Why?
|
| Diuretics | 1 | 2018 | 22 | 0.160 |
Why?
|
| Systole | 2 | 2018 | 87 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2019 | 103 | 0.160 |
Why?
|
| Albuminuria | 1 | 2019 | 174 | 0.160 |
Why?
|
| Actigraphy | 1 | 2017 | 11 | 0.160 |
Why?
|
| Hand Strength | 2 | 2015 | 85 | 0.160 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2014 | 8 | 0.160 |
Why?
|
| Prognosis | 6 | 2019 | 1362 | 0.150 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 59 | 0.150 |
Why?
|
| Cause of Death | 2 | 2015 | 219 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 1 | 2017 | 46 | 0.150 |
Why?
|
| Sex Distribution | 2 | 2011 | 185 | 0.150 |
Why?
|
| Health Status | 3 | 2015 | 368 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2017 | 136 | 0.140 |
Why?
|
| Dyslipidemias | 2 | 2013 | 51 | 0.140 |
Why?
|
| Goals | 1 | 2015 | 36 | 0.130 |
Why?
|
| Managed Care Programs | 2 | 2005 | 38 | 0.130 |
Why?
|
| Analysis of Variance | 3 | 2013 | 454 | 0.130 |
Why?
|
| Motor Skills Disorders | 1 | 2014 | 4 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 636 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.130 |
Why?
|
| Independent Living | 1 | 2015 | 77 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 2 | 2005 | 61 | 0.120 |
Why?
|
| Decision Trees | 1 | 2014 | 23 | 0.120 |
Why?
|
| Medicaid | 2 | 2005 | 83 | 0.120 |
Why?
|
| Sodium Channels | 2 | 2005 | 13 | 0.120 |
Why?
|
| Osteoarthritis, Knee | 2 | 2005 | 80 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 871 | 0.120 |
Why?
|
| ROC Curve | 1 | 2014 | 148 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2014 | 95 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2011 | 2010 | 0.120 |
Why?
|
| Disease Progression | 4 | 2019 | 572 | 0.120 |
Why?
|
| Insulin | 1 | 2015 | 346 | 0.120 |
Why?
|
| Medicare | 2 | 2005 | 185 | 0.120 |
Why?
|
| Asian Americans | 1 | 2013 | 98 | 0.120 |
Why?
|
| Educational Status | 1 | 2013 | 162 | 0.110 |
Why?
|
| Photography | 1 | 2013 | 33 | 0.110 |
Why?
|
| Radius | 1 | 2013 | 21 | 0.110 |
Why?
|
| Bone Density | 4 | 2018 | 182 | 0.110 |
Why?
|
| African Continental Ancestry Group | 2 | 2005 | 350 | 0.110 |
Why?
|
| Tibia | 1 | 2013 | 56 | 0.110 |
Why?
|
| African Americans | 2 | 2013 | 1373 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 195 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 531 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2012 | 160 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2014 | 389 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2017 | 3107 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2018 | 1674 | 0.100 |
Why?
|
| Age Distribution | 1 | 2011 | 197 | 0.090 |
Why?
|
| Observation | 1 | 2010 | 23 | 0.090 |
Why?
|
| Smoking | 1 | 2013 | 427 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2018 | 1300 | 0.090 |
Why?
|
| Public Health | 1 | 2011 | 72 | 0.090 |
Why?
|
| Calcium | 1 | 2012 | 296 | 0.090 |
Why?
|
| Ligands | 1 | 2010 | 81 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 360 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2011 | 159 | 0.090 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 156 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 292 | 0.090 |
Why?
|
| Heart Failure | 2 | 2005 | 567 | 0.090 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 23 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 446 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1218 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 138 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 784 | 0.080 |
Why?
|
| North Carolina | 5 | 2013 | 1422 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 378 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2009 | 139 | 0.080 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2007 | 5 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2007 | 16 | 0.080 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2007 | 14 | 0.080 |
Why?
|
| Hispanic Americans | 1 | 2013 | 904 | 0.080 |
Why?
|
| Injections, Intra-Articular | 1 | 2007 | 12 | 0.070 |
Why?
|
| Physical Fitness | 2 | 2009 | 119 | 0.070 |
Why?
|
| Health Expenditures | 1 | 2007 | 61 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 34 | 0.070 |
Why?
|
| Amiloride | 2 | 2005 | 5 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 106 | 0.070 |
Why?
|
| Prevalence | 2 | 2015 | 892 | 0.070 |
Why?
|
| Gait | 1 | 2007 | 115 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 795 | 0.070 |
Why?
|
| Risk | 2 | 2019 | 289 | 0.070 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 77 | 0.070 |
Why?
|
| Sampling Studies | 2 | 2003 | 40 | 0.070 |
Why?
|
| Adolescent | 5 | 2009 | 3248 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2009 | 855 | 0.070 |
Why?
|
| Oxalates | 1 | 2005 | 2 | 0.070 |
Why?
|
| Drug Utilization Review | 1 | 2005 | 17 | 0.070 |
Why?
|
| Sodium Channel Blockers | 1 | 2005 | 7 | 0.070 |
Why?
|
| C-Reactive Protein | 4 | 2011 | 229 | 0.070 |
Why?
|
| Child | 4 | 2009 | 2209 | 0.070 |
Why?
|
| Movement | 1 | 2005 | 40 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2006 | 59 | 0.070 |
Why?
|
| Kidney Calculi | 1 | 2005 | 25 | 0.070 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2005 | 39 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 641 | 0.070 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2005 | 1 | 0.070 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 17 | 0.060 |
Why?
|
| Muscle Strength | 2 | 2017 | 139 | 0.060 |
Why?
|
| Calibration | 1 | 2004 | 25 | 0.060 |
Why?
|
| Markov Chains | 1 | 2004 | 25 | 0.060 |
Why?
|
| Hypoglycemia | 2 | 2015 | 41 | 0.060 |
Why?
|
| Enalapril | 1 | 2004 | 7 | 0.060 |
Why?
|
| Depression | 1 | 2007 | 378 | 0.060 |
Why?
|
| Statistical Distributions | 1 | 2004 | 5 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 273 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2004 | 26 | 0.060 |
Why?
|
| Physical Conditioning, Animal | 1 | 2004 | 32 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2004 | 47 | 0.060 |
Why?
|
| Comorbidity | 2 | 2003 | 539 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2004 | 122 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2004 | 92 | 0.060 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2003 | 1 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2003 | 5 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Rifampin | 1 | 2003 | 7 | 0.060 |
Why?
|
| Creatinine | 2 | 2019 | 173 | 0.060 |
Why?
|
| Alleles | 1 | 2004 | 251 | 0.060 |
Why?
|
| Intestines | 1 | 2003 | 54 | 0.060 |
Why?
|
| Indiana | 1 | 2003 | 4 | 0.060 |
Why?
|
| Internet | 1 | 2004 | 156 | 0.060 |
Why?
|
| Potassium | 1 | 2002 | 37 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2003 | 71 | 0.060 |
Why?
|
| Diabetes Complications | 2 | 2015 | 171 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2004 | 251 | 0.050 |
Why?
|
| Faculty | 1 | 2002 | 15 | 0.050 |
Why?
|
| Child Behavior Disorders | 1 | 2002 | 11 | 0.050 |
Why?
|
| Genotype | 1 | 2004 | 735 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2003 | 94 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 546 | 0.050 |
Why?
|
| Adiposity | 2 | 2013 | 191 | 0.050 |
Why?
|
| Exercise Tolerance | 2 | 2015 | 110 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 494 | 0.050 |
Why?
|
| Curriculum | 1 | 2002 | 196 | 0.050 |
Why?
|
| Neoplasms | 1 | 2007 | 608 | 0.050 |
Why?
|
| Liver | 1 | 2003 | 464 | 0.050 |
Why?
|
| Diet | 2 | 2017 | 348 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2019 | 16 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 102 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2019 | 183 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 262 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 129 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 26 | 0.040 |
Why?
|
| Homeostasis | 1 | 2018 | 127 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 140 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 26 | 0.040 |
Why?
|
| Glucose | 1 | 2018 | 162 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2017 | 59 | 0.040 |
Why?
|
| Young Adult | 2 | 2017 | 2398 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 126 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 440 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2017 | 168 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 524 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 94 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 222 | 0.030 |
Why?
|
| Survivors | 1 | 2017 | 145 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 251 | 0.030 |
Why?
|
| Kidney | 1 | 2019 | 485 | 0.030 |
Why?
|
| Psychometrics | 1 | 2015 | 129 | 0.030 |
Why?
|
| Cataract Extraction | 1 | 2014 | 8 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 325 | 0.030 |
Why?
|
| Guideline Adherence | 2 | 2005 | 110 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2005 | 237 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2014 | 83 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 14 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2013 | 11 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Movement Disorders | 1 | 2013 | 25 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2013 | 13 | 0.030 |
Why?
|
| Muscle Development | 1 | 2013 | 45 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 96 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 66 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2013 | 89 | 0.030 |
Why?
|
| Adiponectin | 1 | 2013 | 103 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2017 | 562 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2004 | 369 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 425 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2012 | 204 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 111 | 0.020 |
Why?
|
| Formularies as Topic | 1 | 2007 | 3 | 0.020 |
Why?
|
| Tablets | 1 | 2007 | 10 | 0.020 |
Why?
|
| Prescription Fees | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cost Sharing | 1 | 2007 | 10 | 0.020 |
Why?
|
| Drugs, Generic | 1 | 2007 | 13 | 0.020 |
Why?
|
| Cost Control | 1 | 2007 | 17 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 47 | 0.020 |
Why?
|
| Brain | 1 | 2014 | 930 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 175 | 0.020 |
Why?
|
| Exercise Test | 1 | 2007 | 194 | 0.020 |
Why?
|
| Medical Audit | 1 | 2005 | 14 | 0.020 |
Why?
|
| Knee | 1 | 2005 | 31 | 0.020 |
Why?
|
| Spironolactone | 1 | 2005 | 11 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2005 | 46 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 93 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 102 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 224 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 45 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2004 | 32 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2004 | 19 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2004 | 125 | 0.020 |
Why?
|
| Medical Records | 1 | 2004 | 68 | 0.020 |
Why?
|
| Biotransformation | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2003 | 4 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 21 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 223 | 0.010 |
Why?
|
| Midazolam | 1 | 2003 | 11 | 0.010 |
Why?
|
| Random Allocation | 1 | 2004 | 212 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 73 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 27 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 84 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 200 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 93 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 99 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2003 | 169 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 282 | 0.010 |
Why?
|
| Aldosterone | 1 | 2002 | 28 | 0.010 |
Why?
|
| Posture | 1 | 2002 | 53 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 243 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 166 | 0.010 |
Why?
|
| Child Behavior | 1 | 2002 | 25 | 0.010 |
Why?
|
| Renin | 1 | 2002 | 112 | 0.010 |
Why?
|
| Health Promotion | 1 | 2003 | 220 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 461 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1604 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 7297 | 0.010 |
Why?
|